Polypill Strategy for the Treatment of Patients After Acute Coronary Syndromes A Multicenter Randomized Controlled Trial

What this Trial Is About

Researchers are evaluating whether combining standard medications prescribed after acute coronary syndrome (ACS) into a single polypill can improve outcomes following an ACS event. ACS includes conditions like heart attacks and unstable angina and leads to high rates of illness and death. Despite existing treatments, many patients stop taking their medications early, increasing their risk of further problems. This study is a pragmatic, multi-center, randomized trial aiming to test the feasibility and effectiveness of this polypill strategy after ACS. The study compares two groups: one receives a polypill containing aspirin 81 mg, rosuvastatin (40 or 10 mg), and either prasugrel 10 mg or clopidogrel 75 mg, combining dual antiplatelet therapy (DAPT) and a high-intensity statin into one pill taken once daily. The other group receives usual care with these medications prescribed as separate pills. This open-label trial focuses on the subacute period after percutaneous coronary intervention (PCI) in patients discharged on these therapies. Participants will be monitored for 12 months, with researchers assessing outcomes using a win ratio measure at 12 months. They will also track medication adherence and treatment satisfaction during this period. The study involves regular evaluations to observe the effects of the polypill strategy on medication use and cardiovascular events, aiming to address adherence challenges and improve post-ACS care over the course of the year.

A Polypill for Acute Coronary Syndrome